AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

AbbVie Inc. (ABBV), headquartered in North Chicago, Illinois, is a biopharmaceutical company discovers, develops, ...

With the potential for pharmaceutical import tariffs spurring a rush of life sciences investments in the U.S., AbbVie is ...

We came across a bullish thesis on AbbVie Inc. (ABBV) on Substack by Magnus Ofstad. In this article, we will summarize the ...

One quarter after AbbVie raised future sales estimates due to the successes of its immunology portfolio, the company again ...

AbbVie is now pushing Skyrizi and Rinvoq to counter the drop in Humira sales and has forecast the two newer drugs to generate ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other capabilities over the next decade, ...

ABBV's first-quarter earnings and sales beat estimates. The company raises its EPS guidance based on the strong sales ...